Yet, Moshitzky et al. [36] demonstrate that anti-Id Ab is capable of inhibiting the growth of myeloma cells in the absence of membrane-bound Ig in the murine D2 plasmacytoma model suggesting anti-Id Ab could confer clinical benefit. Here, ID1 is linked to plasma cell myeloma.